Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US6402683063
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BHCYJ1
NKTR
Nektar Therapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Nektar Therapeutics
ISIN
US6402683063
TICKER
NKTR
MIC
XNAS
REUTERS
NKTR.OQ
BLOOMBERG
NKTR US
Tue, 07.04.2026       Nektar Therapeutics
US6402683063

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to c...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchas...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you pu...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Nektar Therapeutics
US6402683063

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf of...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Nektar Therapeutics
US6402683063

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment ComplianceNEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action....
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 01.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Nektar Therapeutics
US6402683063

Levi & Korsinsky, LLP alerts investors in Nektar Therapeutics (NASDAQ: NKTR) of a pending securities class action. Class Period: February 26, 2025 through December 15, 2025. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.Nektar shares fell $4.14 per share, or 7.77%, cl...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, March 31, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR)....
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclu...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclus...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Sat, 28.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       Nektar Therapeutics
US6402683063

Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patientsRezpegaldesleukin proof-of-concept data in alopecia areata patients presented as a late-breaking research oral presentationSAN FRANCISCO, March 28, 2026 /PRNewswire/ -- Nektar Therapeutics ...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Nektar Therapeutics
US6402683063

BENSALEM, Pa., March 27, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEKTAR THERAPEUTICS (NKTR), CONTAC...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 26, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclu...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf o...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Nektar Therapeutics
US6402683063

Key Dates and Disclosure Events Shareholders Need to KnowNEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Nektar Therapeutics (NASDAQ: NKTR) to contact the firm. Those who purchased NKTR securities between February 26, 2025 and December 15, 2025 may be entitled to recover damages. Find out if you are e...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 25, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclu...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, March 25, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportunity to lead the securities fraud class action lawsuit....
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Nektar Therapeutics
US6402683063

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment ComplianceNEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action....
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Nektar Therapeutics
US6402683063

Levi & Korsinsky, LLP alerts investors in Nektar Therapeutics (NASDAQ: NKTR) of a pending securities class action. Class Period: February 26, 2025 through December 15, 2025. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500. Nektar shares fell $4.14 per share, or 7.77%...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Nektar Therapeutics
US6402683063

SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 21.03.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 21.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclus...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 21.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Nektar Therapeutics
US6402683063

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31, 2026, in...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - March 19, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclu...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Nektar Therapeutics
US6402683063

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf o...
Read more
Nektar Therapeutics
Technical Analysis Termsheets Terminal
Permalink